Citations

Showing 10 of 108094 citations.

Gastrointestinal: CT and PET/CT imaging of splenic littoral cell angiosarcoma
Nguyen, Ba D.

Mayo Clinic

Journal of Gastroenterology and Hepatology | April 25, 2018 | Volume: 33 | Issue: 8 | Pages: 1432-1432

10.1111/jgh.14145 | PMID 29691898 Get It

A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials
Boers, Maarten , Singh, Jasvinder A. , Cofield, Stacey S. , Bridges, S. Louis , Moreland, Larry W. , O’Dell, James R., Wu, Hongsheng, Curtis, Jeffrey R. , Curtis, Jeffrey R , Singh, Jasvinder A , Moreland, Larry W , Leatherman, Sarah M.

Mayo Clinic

Arthritis Care & Research | April 25, 2018 | Volume: 71 | Issue: 2 | Pages: 319-322

10.1002/acr.23590 | PMID 29691998 Get It

ObjectiveThe Outcome Measures in Rheumatology (OMERACT) 3×3 method analyzes the occurrence of benefit and harm simultaneously at the individual patient level. We applied this method to 2 recent rheumatoid arthritis (RA) trial data sets.MethodsThe Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) and the Rheumatoid Arthritis Comparison of Active Therapies (RACAT) randomized trial outcomes for safety were defined according to OMERACT as having no adverse events (AEs), non‐serious AEs, and serious AEs. Treatment efficacy was defined as good, moderate, or no response. A good treatment response without any AEs was labeled an unqualified success, and no treatment response but at least 1 AE was considered an unmitigated failure. The association between benefit and harm was assessed by chi‐square or exact tests, as appropriate.ResultsIn TEAR, 612 of 755 patients had response data at 48 weeks: 14% of patients experienced unqualified success and 9% had unmitigated failure, with no difference between the treatment arms. Treatment response and AE rates were not correlated. In RACAT, 309 of 353 patients had response data at 48 weeks: 6% of patients experienced unqualified success and 11% had unmitigated failure, with no differences between the treatment arms. Response and AE rates were negatively correlated. The frequency of AEs and serious AEs increased as response decreased (P = 0.008).ConclusionWe found some evidence that clinical response may be reduced by the co‐occurrence of AEs.
Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report
Ruiz‐Heredia, Yanira , Sánchez-Vega, Beatriz, Barrio, Santiago , Linares, María , Rapado, Inmaculada, Braggio, Esteban , Stewart, Keith, Folgueira, María Dolores , Ramos, Ana , Ruiz, Juan , Toldos, Óscar, Martinez-Lopez, Joaquin , Martínez‐López, Joaquín , Martinez-Lopez, Joaquin , Braggio, Esteban , Martinez-Lopez, Joaquin , Yurrita, Luis Collado , Hernández‐Laín, Aurelio

Mayo Clinic

Journal of Oncology Pharmacy Practice | April 25, 2018 | Volume: 25 | Issue: 4 | Pages: 998-1002

10.1177/1078155218769367 | PMID 29690814 Get It

Progressive multifocal leukoencephalopathy rarely occurs in patients with multiple myeloma. Intracranial central nervous system invasion is also an uncommon event in multiple myeloma, occurring in less than 1% of cases. We describe herein an exceptional case of coexisting progressive multifocal leukoencephalopathy and intraparenchymal central nervous system myeloma infiltration. A 73-year-old woman with relapsed multiple myeloma was treated with 15 cycles of lenalidomide and dexamethasone, but therapy had to be stopped because of a hip fracture after a fall. During hospitalization, the patient developed progressive multifocal leukoencephalopathy caused by John Cunningham virus, and a prominent intra-parenchymal CD138-positive infiltrate was detected. VDJ rearrangements of the immunoglobulin heavy chain gene and the mutational profile of plasma cells in bone marrow at the time of diagnosis and in brain biopsy after progression were analyzed by next generation sequencing, showing genetic differences between medullary and extramedullary myeloma cells. The role of long-term treatment with lenalidomide and dexamethasone in the development progressive multifocal leukoencephalopathy or intraparenchymal central nervous system myeloma infiltration remains unknown. However, our results suggest that both events may have arisen as a consequence of treatment-related immunosuppression. Thus, an appropriate clinical approach compatible with the simultaneous treatment of progressive multifocal leukoencephalopathy and multiple myeloma should be developed.
Adult Glottic and Subglottic Stenosis
Kasperbauer, Jan L.

Mayo Clinic

Nihon Kikan Shokudoka Gakkai Kaiho | April 24, 2018 | Volume: 69 | Issue: 2 | Pages: 51-51

10.2468/jbes.69.51 Get It

Acute‐on‐Chronic Liver Failure: Getting Ready for Prime Time?
Bajaj, Jasmohan S. , Moreau, Richard , Kamath, Patrick S. , Vargas, Hugo E. , Arroyo, Vicente , Reddy, K. Rajender , Olson, Jody C. , Karvellas, Constantine , Gustot, Thierry , Karvellas, Constantine , Vargas, Hugo E , Moreau, Richard , Szabo, Gyongyi , Tandon, Puneeta , Lai, Jennifer C. , Wong, Florence

Mayo Clinic

Hepatology | April 24, 2018 | Volume: 68 | Issue: 4 | Pages: 1621-1632

10.1002/hep.30056 | PMID 29689120 Get It

Acute on chronic liver failure (ACLF) is the culmination of chronic liver disease and extrahepatic organ failures, which is associated with a high short‐term mortality and immense health care expenditure. There are varying definitions for organ failures and ACLF in Europe, North America, and Asia. These differing definitions need to be reconciled to enhance progress in the field. The pathogenesis of ACLF is multifactorial and related to interactions between the immunoinflammatory system, microbiota, and the various precipitating factors. Individual organ failures related to the kidney, brain, lungs, and circulation have cumulative adverse effects on mortality and are often complicated or precipitated by infections. Strategies to prevent and rapidly treat these organ failures are paramount in improving survival. With the aging population and paucity of organs for liver transplant, the prognosis of ACLF patients is poor, highlighting the need for novel therapeutic strategies. The role of liver transplant in ACLF is evolving and needs further investigation across large consortia. A role for early palliative care and management of frailty as approaches to alleviate disease burden and improve patient‐reported outcomes is being increasingly recognized. Conclusion: ACLF is a clinically relevant syndrome that is epidemic worldwide and requires a dedicated multinational approach focused on prognostication and management; investigations are underway worldwide to prepare ACLF for prime time. (Hepatology 2018; 00:000‐000)
Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients
Satlin, Michael J. , Chavda, Kalyan D., Baker, Thomas, Shashkina, Elena, Soave, Rosemary, Small, Catherine B. , Jacobs, Samantha E, Westblade, Lars F. , Fowler, Vance G. , Jenkins, Stephen G., Walsh, Thomas J. , Kreiswirth, Barry N. , Jacobs, Samantha E. , Chen, Liang , Jacobs, Samantha E, Shore, Tsiporah B. , Besien, Koen van , Schuetz, Audrey N. , Fowler, Vance G. , Kreiswirth, Barry N

Mayo Clinic

Clinical Infectious Diseases | April 24, 2018 | Volume: 67 | Issue: 11 | Pages: 1720-1728

10.1093/cid/ciy363 | PMID 29701766 Get It

Abstract Background Bacteremia caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) is associated with inadequate empirical therapy and substantial mortality in neutropenic patients. Strategies are needed to identify neutropenic patients at high risk of these infections. Methods From April 2014 to September 2016, we collected perianal swabs, both at admission and weekly thereafter, from patients undergoing hematopoietic stem cell transplantation (HSCT). Patients received prophylactic levofloxacin while neutropenic. Swabs were plated onto selective agar, colonies were identified and underwent antimicrobial susceptibility testing, and phenotypic ESBL testing and polymerase chain reaction for β-lactamase genes were performed on ceftriaxone-resistant Enterobacteriaceae. We then determined the prevalence of pre-transplant ESBL-E colonization and risk of ESBL-E bacteremia. Colonizing and bloodstream isolates from patients with ESBL-E bacteremia underwent multilocus sequence typing and pulsed-field gel electrophoresis. Results We analyzed 312 patients, including 212 allogeneic and 100 autologous HSCT recipients. Ten percent (31/312) of patients had pre-transplant ESBL-E colonization. Susceptibility rates of colonizing ESBL-E were: levofloxacin, 25%; cefepime, 9%; piperacillin-tazobactam, 84%; and meropenem, 97%. Of 31 patients colonized with ESBL-E pre-transplant, 10 (32%) developed ESBL-E bacteremia during their transplant admission, compared to 1 (0.4%) of 281 patients not colonized with ESBL-E (P < .001). All bloodstream ESBL-E were levofloxacin-resistant and colonizing and bloodstream isolates from individual patients had identical genotypic profiles. Conclusions HSCT recipients who are colonized with levofloxacin-resistant ESBL-E pre-transplant and receive levofloxacin prophylaxis have high rates of bacteremia from their colonizing strain during neutropenia. Assessing for ESBL-E colonization in neutropenic patients could lead to optimization of empirical antibacterial therapy.
Early Hospital Discharge After Helicopter Transport of Pediatric Trauma Patients
Fahy, Aodhnait S. , Polites, Stephanie F. , Parker, Maile E., Ishitani, Michael B., Moir, Christopher R. , Berns, Kathleen S., Zietlow, Scott P., Jenkins, Donald H. , Zielinski, Martin D. , Berns, Kathleen, Thiels, Cornelius A.

Mayo Clinic

Pediatric Emergency Care | April 24, 2018 | Volume: 36 | Issue: 12 | Pages: e709-e714

10.1097/pec.0000000000001481 | PMID 29698341 Get It

Objectives Helicopter air ambulance (HAA) of pediatric trauma patients is a life-saving intervention. Triage remains a challenge for both scene transport and interhospital transfer of injured children. We aimed to understand whether overtriage or undertriage was a feature of scene or interhospital transfer and how in or out of state transfers affected these rates. Methods Children (<18 years) who underwent trauma activation at a level I trauma center between 2011 and 2013 were identified and reviewed. Patients transported by HAA were compared with those transported by ground ambulance (GA). Results Of 399 pediatric patients (median age, 10.4 years; range, 0.1–17 years; 264 male [66%]), 71 (18%) were transported by HAA. Seventy-two percent of HAA patients went to the intensive care unit or the operating room from the trauma bay or suffered in-hospital mortality (vs 42% GA, P < 0.001). More patients were overtriaged (HAA with injury severity score [ISS] of <15) from interhospital transfers than from the scene (25% vs 3%, P = 0.002). Undertriage (GA with ISS >15) was acceptable at 5% from the scene and 14% from interhospital transfers (P = 0.08). Overtriage of patients with ISS less than 15 to HAA was significantly lower from in-state hospitals (22%) than out-of-state hospitals (45%) (P = 0.02). Undertriage of patients with ISS greater than 15 to GA was also lower from in-state hospitals (20%) versus out-of-state hospitals (38%) (P = 0.03). Conclusions Triage of pediatric trauma patients to HAA remains difficult. There remains potential for improvement, particularly as regards interhospital HAA overtriage, but well developed transfer protocols (such in-state protocols) may help.
CHECKPOINT INHIBITOR IMMUNE THERAPY
Orloff, Marlana , Sato, Takami , Shields, Jerry A., Dalvin, Lauren A. , Shields, Carol L.

Mayo Clinic

Retina | April 24, 2018 | Volume: 38 | Issue: 6 | Pages: 1063-1078

10.1097/iae.0000000000002181 | PMID 29689030 Get It

Purpose: To review immune checkpoint inhibitor indications and ophthalmic side effects. Methods: A literature review was performed using a PubMed search for publications between 1990 and 2017. Results: Immune checkpoint inhibitors are designed to treat system malignancies by targeting one of three ligands, leading to T-cell activation for attack against malignant cells. These ligands (and targeted drug) include cytotoxic T-lymphocyte antigen-4 (CTLA-4, ipilimumab), programmed death protein 1 (PD-1, pembrolizumab, nivolumab), and programmed death ligand-1 (PD-L1, atezolizumab, avelumab, durvalumab). These medications upregulate the immune system and cause autoimmune-like side effects. Ophthalmic side effects most frequently manifest as uveitis (1%) and dry eye (1–24%). Other side effects include myasthenia gravis (n = 19 reports), inflammatory orbitopathy (n = 11), keratitis (n = 3), cranial nerve palsy (n = 3), optic neuropathy (n = 2), serous retinal detachment (n = 2), extraocular muscle myopathy (n = 1), atypical chorioretinal lesions (n = 1), immune retinopathy (n = 1), and neuroretinitis (n = 1). Most inflammatory side effects are managed with topical or periocular corticosteroids, but advanced cases require systemic corticosteroids and cessation of checkpoint inhibitor therapy. Conclusion: Checkpoint inhibitors enhance the immune system by releasing inhibition on T cells, with risk of autoimmune-like side effects. Ophthalmologists should include immune-related adverse events in their differential when examining cancer patients with new ocular symptoms.
External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
Cheung, Angela , Gulamhusein, Aliya , Juran, Brian D., Schlicht, Erik M., McCauley, Bryan M. , Atkinson, Elizabeth J. , Cheung, Angela C, de Andrade, Mariza, Lazaridis, Konstantinos N. , Andrade, Mariza de

Mayo Clinic

Hepatology Communications | April 24, 2018 | Volume: 2 | Issue: 6 | Pages: 676-682

10.1002/hep4.1186 | PMID 29881819 Get It

The United Kingdom‐Primary Biliary Cholangitis (UK‐PBC) risk scores are a set of prognostic models that estimate the risk of end‐stage liver disease in patients with PBC at 5‐, 10‐ and 15‐year intervals. They have not been externally validated outside the United Kingdom. In this retrospective, external validation study, data were abstracted from outpatient charts and discrimination and calibration of the UK‐PBC risk scores were assessed. A total of 464 patients with PBC treated with ursodeoxycholic acid were included. The median diagnosis age was 52.4 years, and 88% were female patients. The cumulative incidence of events was 6%, 9%, and 15% at 5, 10, and 15 years, respectively. Concordance (c‐statistic) was 0.88, 0.85, and 0.84 using the 5‐, 10‐ and 15‐year risk scores, respectively, which was slightly lower than values observed in the United Kingdom validation cohort. Using the 5‐year risk score, more events were observed than predicted (25 versus 16.8; P = 0.046); using the 10‐year risk score, there was no difference between the observed and predicted number of events (35 versus 44.9; P = 0.14); conversely, using the 15‐year risk score, fewer events were observed than predicted (46 versus 67.5; P = 0.009). Limiting evaluation by the 15‐year UK‐PBC risk score to those with >10 years of follow‐up demonstrated no difference between observed and predicted events. Using the 5‐year risk score, patients within the highest quartile had statistically significant worse event‐free survival compared to the rest of the cohort: 82% versus 98% at 5 years, 73% versus 97% at 10 years, and 58% versus 93% at 15 years. Conclusion: In patients assessed at a North American tertiary medical center, the UK‐PBC risk score had excellent discrimination and was reasonably calibrated both in the short and long term. (Hepatology Communications 2018;2:676‐682)
Novel Arthroscopic Tendon Transfers for Posterosuperior Rotator Cuff Tears
Wagner, Eric R. , Welp, Kathryn M., Elhassan, Bassem T. , Higgins, Laurence D. , Warner, Jon J.P. , Warner, Jon J P , Wagner, Eric R , Woodmass, Jarret Murray , Chang, Michelle J.

Mayo Clinic

JBJS Essential Surgical Techniques | April 24, 2018 | Volume: 8 | Issue: 2 | Pages: e12

10.2106/jbjs.st.17.00062 | PMID 30233984 Get It

Background: Massive irreparable rotator cuff tears in both the primary and the revision setting are challenging problems. There remains controversy over the ideal treatment methods for these patients. In the case of an irreparable posterosuperior rotator cuff tear, tendon transfers 1–12 have emerged as a reliable option, with a durable outcome. The most commonly used tendon transfer options are the latissimus dorsi (LD) 1–6 and the lower trapezius (LT) 12 . Description: The LD transfer is performed by first harvesting the LT tendon from the humeral shaft. It is critical to release the many adhesions to the muscle belly as well as to separate it from the teres major muscle. The tendon is then transferred intra-articularly, in an interval between the deltoid and the teres minor. The tendon is anchored arthroscopically after preparation of the anterolateral aspect of the tuberosity. The LT transfer is performed by harvesting the LT muscle and tendon off its insertion on the medial aspect of the scapular spine. It should be mobilized to maximize excursion by releasing adhesions. An Achilles tendon allograft is anchored into the anterior aspect of the greater tuberosity arthroscopically. The Achilles tendon is then secured to the LT tendon. Alternatives: In addition to tendon transfer, options include: Partial or complete attempted repair 13–17 . Augmentation or bridging with allografts 18–23 . Superior capsular reconstruction 24 . Subacromial balloon 25 . Rationale: There remains a paucity of literature comparing tendon transfers with alternatives. However, when considering a tendon transfer, certain principles are critical in order to achieve an optimal outcome: The recipient and transferred tendons must have similar musculotendinous excursion. The recipient and transferred tendons should have similar lines of pull. One tendon (the transferred) should be designed to replace 1 function (of the recipient). The function of the transferred tendon and muscle should be expendable without substantial donor site morbidity. The strength of the transferred muscle must be at least grade 4. When deciding between the LT and LD transfer, certain considerations should be taken into account. The LD transfer has a proven history of successfully treating massive irreparable posterosuperior rotator cuff tears in studies with long-term follow-up 1–6 . Alternatively, although the LT transfer has only recently gained popularity, it has the advantage of “in-phase” muscle function, since the trapezius naturally contracts during shoulder external rotation. Furthermore, its line of pull almost completely mimics the infraspinatus.